Did You Know...
...that power steering was invented by independent inventor Francis W. Davis? As chief engineer in the 1920s of the truck division of the Pierce Arrow Motor Car Company, he saw how hard it was to steer heavy vehicles. So that he would be able to keep the profits from his future invention, Davis left his job, rented a small engineering shop in Waltham, Mass., and developed a hydraulic power steering system that led to power steering.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120129717 | Collection and Methods For Its Use The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select ag... | 05/24/2012 |
| 20120128663 | Fc VARIANTS THAT EXTEND ANTIBODY HALF-LIFE The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.... | 05/24/2012 |
| 20120129219 | Antibody Molecules Which Bind Human IL-17 The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods of producing the antibody molecules.... | 05/24/2012 |
| 20120128676 | MUC1 ANTIBODIES The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to ... | 05/24/2012 |
| 20120128669 | MONOVALENT, BIVALENT AND TRIVALENT ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) NANOBODY CONSTRUCTS FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid seque... | 05/24/2012 |
| 20120128591 | ANTI-FAP ANTIBODIES AND METHODS OF USE The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.... | 05/24/2012 |
| 20120107325 | IL-17 Antagonistic Antibodies An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 m... | 05/03/2012 |
| 20120107320 | ANTIBODIES SPECIFICALLY DIRECTED TO THE SOLUBLE FORM OF CTLA-4 The invention provides materials and methods relating to antibodies specific for the soluble form of CTLA-4 (sCT-LA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.... | 05/03/2012 |
| 20120107324 | TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases assoc... | 05/03/2012 |
| 20120107364 | ANTIBODY HAVING ANTI-CANCER ACTIVITY By utilizing an SST-REX method, a cDNA encoding a protein expressed on a cell surface or secreted from the cell was selected from a cDNA library derived from a cancer cell line. Monoclonal antibodies against the protein encoding the selected cDNA were prepared. The in v... | 05/03/2012 |
| 20120107928 | Antibody Inhibitors of GDF-8 and Uses Thereof The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disor... | 05/03/2012 |
| 20120107330 | ANTAGONISTS, USES & METHODS FOR PARTIALLY INHIBITING TNFR1 The present invention relates to anti-Tumor Necrosis Factor 1 (TNFR1, p55, CD120a, P60, TNF receptor superfamily member 1A, TNFRSF1A) antagonists for partially inhibiting TNFR1 useful for the treatment and/or prevention of TNFR1-mediated diseases or conditions such as a... | 05/03/2012 |
| 20120107933 | ANTI-MESOTHELIN ANTIBODIES The present invention provides monoclonal anti-mesothelin antibodies and antibody fragments and methods for their use. The antibodies can be completely human.... | 05/03/2012 |
| 20120108795 | Antibodies Binding Human Collagen II The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.... | 05/03/2012 |
| 20120107234 | Pan-HER Antibody Composition The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody com... | 05/03/2012 |
| 20120082662 | ANTI-CMET ANTAGONISTS The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... | 04/05/2012 |
| 20120082664 | OPTIMIZED ANTIBODIES THAT TARGET CD19 The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Als... | 04/05/2012 |
| 20120082680 | ANTAGONISTS OF PCSK9 Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associa... | 04/05/2012 |
| 20120082666 | ANTIBODY COMPOSITIONS AND METHODS OF USE The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same.... | 04/05/2012 |
| 20120082663 | ANTI-CMET ANTAGONISTS The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... | 04/05/2012 |
| 20120082670 | CD33 BINDING AGENTS The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS... | 04/05/2012 |
| 20120083015 | ANTIBODIES AGAINST HUMAN TWEAK AND USES THEREOF An antibody binding to TWEAK comprising as heavy chain variable domain a CDR3H selected from the group consisting of SEQ ID NO: 8, 16 or 24.... | 04/05/2012 |
| 20120082679 | ANTAGONISTS OF PCSK9 Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associa... | 04/05/2012 |
| 20120082681 | ANTI-IL12RBETA1 ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists... | 04/05/2012 |
| 20120070439 | ANTIGEN-BINDING PROTEINS The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof.... | 03/22/2012 |
| 20120070447 | METHODS OF ADMINISTERING / DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncyt... | 03/22/2012 |
| 20120073004 | Hybrid Light Chain Mice Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice tha... | 03/22/2012 |
| 20120070457 | Polypeptides from neisseria meningitidis Polypeptides comprising Neisseria meningitidis amino acid sequences. Over 36000 meningococcal polypeptide sequences are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be usedin medicine for treati... | 03/22/2012 |
| 20120070446 | RSV SPECIFIC BINDING MOLECULE The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.... | 03/22/2012 |
| 20120052078 | GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38 The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.... | 03/01/2012 |
| 20120052072 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding... | 03/01/2012 |
| 20120052060 | Human Antibody Molecules For IL-13 Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, a... | 03/01/2012 |
| 20120052073 | Antibodies Directed to Angiopoietin-2 And Uses Thereof Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin m... | 03/01/2012 |
| 20120052566 | ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.... | 03/01/2012 |
| 20120045443 | Agonist anti-trk-c monoclonal antibodies The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including ... | 02/23/2012 |
| 20120046450 | Modulation Of Antibody Effector Function By Hinge Domain Engineering The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector functi... | 02/23/2012 |
| 20120045438 | ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.... | 02/23/2012 |
| 20120045437 | MONOCLONAL ANTIBODIES THAT INHIBIT THE Wnt SIGNALING PATHWAY AND METHODS OF PRODUCTION AND USE THEREOF Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed.... | 02/23/2012 |
| 20120047585 | HCO32 AND HCO27 AND RELATED EXAMPLES The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-ce... | 02/23/2012 |
| 20120045390 | Composition and Methods for the Diagnosis and Treatment of Tumor The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... | 02/23/2012 |
